Haemonetics (HAE) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Haemonetics

NYSE•Healthcare•Medical Devices

$106.24+0.04(<0.01%)Pre-market

Market Cap

$4.92B

P/E

51.1x

P/S

3.6x

P/B

5.9x

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.

How this company scores

AverageMetricSide Score: 57/100

Strongest: Cash & Earnings Quality (25/25); weakest: Growth (8/25).

Profitability15/25

Growth8/25

Balance Sheet & Red Flags9/25

Cash & Earnings Quality25/25

Strengths

Rising free cash flowCash-backed earningsConsistent free cash flowImproving margins

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 51.1x5y range 13.6x – 119.9x

Currently above its 20-quarter median.

P/S · 3.6x5y range 1.7x – 3.9x

Currently near its 20-quarter median.

P/B · 5.9x5y range 2.7x – 5.9x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

Operating margins dropped 31.6% over recent quarters — a sharp decline suggesting serious cost or pricing challenges.

Leverage Risk

Watch

Debt-to-equity has risen 33.8% recently — increasing financial risk even if the current ratio is manageable.

Price & Volume

Market Cap $4.92B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $1.35B
Q. Revenue: $339.38M
TTM EBITDA: $270.39M
TTM Op. Income: $160.32M
Q. Op. Income: $57.46M
TTM Net Income: $96.29M
Q. Net Income: $33.01M
EPS: $0.73
Shares Out.: $45.36M

$1.35B in TTM revenue grew 0.4% YoY, reaching $339.38M last quarter. TTM EBITDA of $270.39M and TTM operating income of $160.32M show growth is flowing through to the bottom line. TTM net income of $96.29M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 2 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 59.8%
EBITDA Margin: 24.9%
Op. Margin: 16.9%
Net Margin: 9.7%

Op. margin of 16.9% is up 0.2% YoY — cost efficiency is improving. Net margin at 9.7% and gross margin of 59.8% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 1% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 51.1x
P/S Ratio: 3.6x
P/B Ratio: 5.9x

At 51.1x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 3.6x and P/B of 5.9x provide additional context. P/E sits above typical market levels while revenue growth is below 5%. Across the last 8 quarters, P/E has risen for 3 consecutive quarters — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $2.37B
Cash: $223.38M
Long-Term Debt: $1.17B
Book Value: $837.10M
D/E Ratio: 1.4
Debt/EBITDA: 13.8

With $2.37B in assets and $1.17B in long-term debt, D/E is 1.4and book value is $837.10M — moderate leverage. Over the past year, debt/equity is up 34% — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $52.32M
TTM Free Cash Flow: $291.22M
FCF Margin: 21.5%
FCF / Net Income: 3.0

TTM FCF of $291.22M on $52.32M in operating cash flow. The FCF / Net Income ratio of 3.0x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is up 54% — an improving trend.